Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
Status:
Not yet recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
In this clinical trial adult patients diagnosed with follicular lymphoma and relapse or
progression of disease within 24 months of starting first line treatment will be treated with
mosunetuzumab. This is a bispecific antibody, a new type of immunotherapy that redirects the
bodies own immune cells (T-cells) to attack and kill the lymphoma cells. The main question
the trial aims to answer is if mosunetuzumab works better than standard treatments in this
sub-group of patients. Patients will receive mosunetuzumab as injections in the abdominal
subcutaneous fat once a week for the three first doses, then every third week 7 times. If all
signs of disease are gone as evaluated by PET-CT images, the treatment is stopped. If signs
of disease remain on PET-CT images, the patients can receive treatment every third week for
up to a total of one year. After the end of treatment, patients are followed two years in the
trial for signs of progression or relapse.